Your session is about to expire
← Back to Search
Anti-infective Agent
Metronidazole 500 mg for Bacterial Vaginosis
Phase 4
Waitlist Available
Research Sponsored by Ohio State University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, approximately 9.5 months
Awards & highlights
Study Summary
This trial is testing whether the antibiotic metronidazole is effective in treating bacterial vaginosis (BV) in pregnant women.
Eligible Conditions
- Bacterial Vaginosis
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ through study completion, approximately 9.5 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, approximately 9.5 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Evaluating Composite of Chorioamnionitis, Postpartum Endometritis, SSI, Wound Infection, or Other Post-cesarean Infections (Occurring Within 6 Weeks After Delivery)
Secondary outcome measures
Evaluating Incidence of Adverse Events
Evaluating Incidence of Confirmed Sepsis for Newborns
Evaluating Incidence of Individual Infections.
+6 moreTrial Design
2Treatment groups
Active Control
Placebo Group
Group I: Metronidazole 500 mgActive Control1 Intervention
Participants in this arm will receive metronidazole 500 mg twice daily, orally for 7 days
Group II: PlaceboPlacebo Group1 Intervention
Participants in this arm will receive placebo
Find a Location
Who is running the clinical trial?
Ohio State UniversityLead Sponsor
827 Previous Clinical Trials
502,735 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger